Introduction
Squamous cell carcinoma of the uterine cervix is one of the most frequent cancers affecting women worldwide. The carcinomas arise from cervical intraepithelial neoplasia (CIN) lesions. If left untreated, CIN lesions of all grades (I-III) may progress to invasive and metastatic cancer.
Infection with high-risk human papilloma virus (HPV) types, in particular HPV16 and HPV18, is a crucial step in the etiology of cervical carcinomas (zur Hausen, 1996) . The oncogenic process is mainly driven by the viral proteins E6 and E7, which deregulate cell cycle control through inactivation of the tumor suppressor gene products p53 (by E6) and pRB (by E7); furthermore, they activate telomerase (E6) and induce centrosome aberrations and chromosome instability (for reviews, see Duensing and Munger, 2002; Fehrmann and Laimins, 2003; Duensing and Munger, 2004) .
Despite infection with high-risk HPV subtypes, only a small and unpredictable number of dysplastic lesions progress to invasive cancer, indicating that additional genetic alterations affecting cellular oncogenes and tumor suppressor genes are involved in tumorigenesis (zur Hausen, 1995) . Chromosomal sites displaying recurrent losses in tumors are likely to harbor tumor suppressor genes. Loss of heterozygosity (LOH) analyses of invasive cervical carcinomas have indicated frequent losses of chromosomal arms 3p, 6p, 11q and 17p among others (Mitra et al., 1994; Mullokandov et al., 1996; Rader et al., 1996; Kersemaekers et al., 1998a, b; Harima et al., 2001) . Although a number of putative tumor suppressor genes map to these sites, the losses could not yet be attributed to specific genes.
Several groups have included analysis of the chromosomal arm 18q in their LOH studies and have reported LOH frequencies of 10-37% for this chromosomal arm (Mitra et al., 1994; Mullokandov et al., 1996; Rader et al., 1996; Kersemaekers et al., 1998a, b; Dellas et al., 1999; Harima et al., 2001) . More importantly, three of these studies have suggested an association of 18q loss with poor prognosis (Kersemaekers et al., 1998b; Dellas et al., 1999; Harima et al., 2001) . One of the genes located on chromosome 18q21 is the tumor suppressor gene Smad4. Functional inactivation of Smad4 is of major importance in gastrointestinal malignancies. Inactivation of Smad4 occurs in one-half of pancreatic adenocarcinomas , in one-third of metastatic colorectal cancers (Miyaki et al., 1999) , in every fourth carcinoma of the small intestine (Blaker et al., 2002) and in smaller subsets of other tumor types Hahn et al., 1998) . Smad4 is a central transmitter of TGF-b responses and loss of Smad4 has been hypothesized to underlie TGF-b resistance of tumor cells.
In the present paper, we investigated the Smad4 expression status in panels of cervical cancer cell lines, in CIN lesions and in primary squamous cervical carcinomas, each. We report Smad4 deficiency in four out of 13 cervical cancer cell lines. The Smad4 status, however, did not correlate with TGF-b responsiveness. In addition, 10 out of 41 cases of squamous cell carcinoma exhibited Smad4 loss, whereas all normal epithelia and CIN lesions showed moderate or strong Smad4 expression. These data indicate that loss of Smad4 may play a significant role in cervical carcinogenesis.
Results

Smad4 deficiency in cervical carcinoma cell lines
Based on the observation of frequent LOH at 18q in cervical cancers, we analysed Smad4 expression in a panel of 13 individual human cervical carcinoma cell lines. The Smad4 protein was readily detected by Western blot analysis in eight of 13 cell lines, but was completely lacking in the other five cell lines HeLa, MRI-H215, HT-3, C4-I and C4-II (Figure 1 ).
To begin to decipher the molecular basis underlying Smad4 deficiency, we performed Northern blot analysis. All eight cell lines positive for Smad4 protein displayed the characteristic pattern of Smad4-specific transcripts (Schwarte-Waldhoff et al., 1999) , namely a main transcript of approximately 3.5 kb in size and a high molecular weight transcript (Figure 2) . No Smad4-specific transcripts could be detected in C4-I, C4-II and HeLa, whereas HT-3 and MRI-H215 cells expressed Smad4 transcripts of a shorter size and at decreased levels.
Smad4-negative HeLa mutant
The absence of Smad4 protein and mRNA in HeLa was surprising, since lack of Smad4 expression had not been reported previously for this cell line (Lee et al., 2001; Maliekal et al., 2003) . In order to clarify this apparent paradox, we analysed the Smad4 gene and its expression in HeLa cells obtained from different sources. All these cells were unambiguously identified as HeLa because they show the HPV18 DNA integration and expression pattern unique to HeLa (data not shown and Figure 3) . The results clearly demonstrated the existence of two HeLa variants, one containing and expressing the Smad4 gene, and the other harboring a homozygous Smad4 deletion (Figure 3 ). The APM-1 gene (Reuter et al., 1998) is located near the Smad4 gene (at a distance of about 2.8 Mb) on chromosome 18q21. Hybridization with an APM-1 probe was positive for both HeLa variants ( Figure 3 ). We conclude from these results that the Smad4-positive variant represents the original HeLa, whereas the Smad4-negative variant is a mutant harboring a deletion of a small chromosomal region including the Smad4 locus. We have worked with the Smad4-positive HeLa cells for all subsequent analyses.
Intronic insertion in C4-I and C4-II
Using the genomic DNA of all 13 cervical carcinoma cell lines for Southern analysis, hybridization with a Smad4 cDNA probe (exons 1-11) revealed the absence or alteration of specific HindIII fragments in all those cell lines that showed either lack of Smad4 expression (C4-I, C4-II) or truncated transcripts (HT-3, MRI-H215) (Figure 4) . Deduced from the HindIII restriction map of the Smad4 gene, the mutations could be localized within the gene regions harboring exons 1-4 (C4-I, C4-II), exons 10 and 11 (MRI-H215) or exons [8] [9] [10] [11] .
In cell lines C4-I and C4-II, the 9.5 kb HindIII fragment, which harbors exons 1-3, was missing and an additional band of approximately 8 kb in size Figure 1 Smad4 protein in cervical carcinoma cell lines. Smad4 protein was detected by Western blot analysis using the anti-Smad4 antibody B8. To control for equal protein loading, the gel was stained with Ponceau, as shown in the lower panel Figure 2 Smad4 mRNAs in cervical carcinoma cell lines. Total RNA was separated on a 1% agarose gel, and Northern blot hybridization was performed with a radiolabelled Smad4 cDNA probe. The horizontal bars indicate the positions of the 28S and 18S rRNAs. RNA loading and integrity was controlled by rehybridization with a GAPDH probe Smad4 deficiency in cervical carcinoma cells SE Baldus et al appeared (Figure 4 ). Additional Southern blots with EcoRI and EcoRI/HindIII double-digested DNA could narrow down the genetic alteration to exon 3-intron 3 sequences (data not shown). C4-I and C4-II showed identical hybridization patterns indicating that they contain the same mutation. The two cell lines are derivatives from a single primary tumor, but they differ from each other in many respects (Auersperg et al., 1989) .
To further map the suspected deletion, genomic PCR assays of C4-I DNA were performed with primer pairs for exons 3 and 4 and with additional primer pairs distributed over intron 3. Surprisingly, all of these fragments could be amplified. Subsequent Southern hybridizations revealed that not a deletion but rather a DNA insertion within intron 3 had occurred which has increased the intron size by about 1.5 kb. As shown in Figure 5 , the intron-3-specific probes hybridized in C4-I/ C4-II DNA either to the 8 kb fragment or to a novel 3 kb fragment, whereas all of them hybridized to the 9.5 kb fragment in the control DNA. Since experiments aimed at amplifying the altered part by long-range PCR failed, the detailed structure of the inserted sequence could not be unravelled.
3
0 Deletions and truncated mRNAs in MRI-H215 and HT-3
The Southern hybridization pattern of HT-3 and MRI-H215 DNA (Figure 4 and data not shown) suggested deletions in the 3 0 region of the Smad4 gene in both of these cell lines. Genomic PCR of exon sequences was positive for exons 1-9 but negative for exons 10 and 11 (data not shown). Southern blot analysis using exon 11 sequences as a hybridization probe confirmed homozygous deletion of 3 0 sequences in both cell lines (data not shown).
The cell lines HT-3 and MRI-H215 express truncated Smad4 mRNAs: a single RNA species of 2.3 kb in HT-3, and two transcripts of ca. 2.0 and 3.1 kb in MRI-H215 (Figure 6a ). According to the genomic data, these truncated mRNAs should harbor mutated 3 0 ends. For further characterization, the 3 0 ends were amplified by reverse transcription (RT)-PCR, cloned and sequenced. sequences derived from downstream 18q21 genomic regions. The 3 0 sequence of the HT-3 Smad4 fusion mRNA is derived from a genomic locus at about 35 kb downstream of exon 9 of Smad4 and is composed entirely of repetitive sequences. In the MRI-H215 Smad4 fusion mRNA, a unique sequence derived from a genomic locus at 661 kb downstream is spliced to exon 9 of Smad4. This unique sequence is not present in any cDNA sequence stored in publicly available databases and thus is probably not normally transcribed. We could verify by RT-PCR that the altered 3 0 ends are genuine parts of the truncated Smad4 mRNAs (data not shown). The structures of the hybrid Smad4 mRNAs are presented in Figure 6b .
Exons 10 and 11 encode the carboxy-terminal 116 amino-acid residues of Smad4 protein (total: 552 residues). With the unrelated downstream sequences spliced to exon 9, the upstream Smad4 ORF (encoding the amino-terminal 436 residues) is continued in frame by additional 53 (HT-3) and 18 (MRI-H215) amino-acid residues, respectively. The 3 0 -truncated Smad4 proteins, however, have never been detected in Western blots (see Figure 1 ).
TGF-b response in cervical carcinoma cell lines
Loss of Smad4 is one of the molecular mechanisms believed to underlie TGF-b resistance in cancer cells. To 
Smad4 and HPV
The results of our Smad4 analyses are summarized in Table 1 . Data from work published by others concerning HPV status and integration sites as well as additional molecular alterations are also listed. There is no evidence for a correlation of HPV status and Smad4 expression. Moreover, Smad4 alterations at the DNA level apparently are not due to integration of HPV sequences: cell lines with altered Smad4 DNA are either HPV negative (HT-3) or have integration sites on 
Smad4 expression in normal and neoplastic cervical tissues
The high incidence of Smad4 inactivation in human cervical carcinoma cell lines prompted us to study Smad4 expression in primary human cervical squamous carcinoma specimens and in CIN lesions. We chose Figure 8 , Table 2 ). Staining intensity was accentuated in the basal and parabasal layers. Endocervical epithelium and glands also exhibited nuclear and diffuse cytoplasmic positivity. CIN with mild or moderate dysplasia (CIN1 or CIN2, n ¼ 20) showed a similar expression pattern. In most cases, moderate or strong SMAD4 staining intensity was retained in more than 65% of the neoplastic cells. Four out of 20 specimens containing severe dysplastic intraepithelial neoplasia (CIN3) exhibited a slight reduction in the percentage of Smad4-positive cells (Table 2) . Importantly, in most cases of cervical squamous cell carcinomas under study (n ¼ 41), the expression of SMAD4 was reduced (Figure 8 ). Only five cases showed a positivity in more than 65% of the tumor area, and 26 cases had Table 2 ). A total of 10 cases were scored as negative, and either completely lacked Smad4 protein expression (three cases) or expressed the protein in less than 5% of the tumor cells (seven cases).
Discussion
Prompted by reports of significant LOH frequencies on chromosome 18q in cervical carcinomas, we performed an analysis of Smad4 in 13 individual cervical cancer cell lines, 40 precancerous CIN lesions and 41 primary squamous cervical carcinoma specimens. Functional inactivation of Smad4 was found in four of the 13 cell lines and was due to homozygous loss of 3 0 exons in two of them and presumably to insertional inactivation in intron 3 in the other two. The results from Smad4 immunostaining in primary samples of human cervical squamous cell carcinomas are in good agreement with the frequency of Smad4 inactivation in cervical cancer cell lines: 10 out of 41 cases were scored as Smad4 negative and 26 cases showed reduced expression, whereas all CIN lesions retained normal Smad4 expression levels. Thus, the findings in this study uncover yet another tumor entity where loss of Smad4 appears to play a significant role in the carcinogenic process.
Infection with high-risk HPVs and expression of the viral oncoproteins E6 and E7, later followed by integration of viral DNA into the host genome are crucial steps in the etiology of cervical carcinomas (zur Hausen, 1996) . Chromosome 18q21 has been shown to harbor the integration site for HPV68 DNA in the cell line ME180, leading to insertional mutagenesis of the cellular zinc-finger gene APM-1 (Reuter et al., 1998) which neighbors the Smad4 gene. Yet, we did not find any evidence for a correlation of Smad4 and HPV status or of Smad4 status and HPV integration site in our panel of cell lines. ME180 cells show 'normal' Smad4 expression. The four Smad4-deficient cell lines include two closely related HPV18-positive lines (C4-I and C4-II), one HPV45-positive (MRI-H215) and one HPV-negative line (HT-3). The HPV integration sites map to chromosomes 8q and 2q, respectively, excluding the possibility that HPV integration had led to functional inactivation of Smad4.
The structural alterations in the Smad4 gene detected in cervical cancer cell lines with absent or altered Smad4 expression have been analysed in detail. An insertion in intron 3 of approximately 1.5 kb in size has been detected in C4-I and C4-II cells. The finding that both lines harbor the same genetic alteration in the Smad4 gene indicates that this alterations had been already present in the primary tumor from which both cell lines were derived. This contention is important since the acquisition of additional genetic alterations in tumor cells upon propagation in vitro and in vivo has previously been reported (Reyes et al., 1996; Villanueva et al., 1998) . This is obviously the case in the Smad4-negative HeLa variant identified in our study. This variant seems to be derived from the Smad4-positive original HeLa cell line through deletion of a short fragment of chromosome 18q21 upon passaging in vitro.
We do not know whether the insertion in intron 3 of the Smad4 gene is responsible for lack of Smad4 expression in C4-I and C4-II cells. Insertional inactivation of the p53 tumor suppressor gene involving an Alu element, which resides in intron 1 of the p53 gene, has been described in Hs766T pancreatic carcinoma cells (Slebos et al., 1998) . Interestingly, three Alu repeats are present in Smad4 intron 3. Owing to the failure to amplify the altered intron 3 sequences from C4-I DNA, however, we were unable to exactly decipher the genomic alteration. Additional genomic alterations might also be present in further upstream Smad4 sequences. The Smad4 gene possesses two noncoding 5 0 exons approximately 16 kb upstream from 'exon 1 0 ; these sequences and the intervening introns have not yet been analysed. Moreover, there is only a limited number of published reports on putative Smad4 promoter sequences. These do not, however, cover sequences upstream of the most 5 0 exon of Smad4 (Minami et al., 1998; Zhou et al., 1999; Roth et al., 2000) . Our own preliminary studies of putative promoter sequences by bisulfite sequencing did not provide evidence for hypermethylation in C4-I and C4-II.
Cell lines MRI-H215 and HT-3 are new examples of those cases where Smad4 is functionally inactivated through homozygous deletion (Iacobuzio-Donahue et al., 2004) . The homozygous loss in both cell lines does not cover the entire gene but starts in (different parts of) intron 9. Intragenic Smad4 deletions have also been detected in a pancreatic carcinoma cell line and in xenografted primary pancreatic adenocarcinomas (Iacobuzio-Donahue et al., 2004) . Cell lines and xenografted tissues are the two scenarios, where homozygous deletions can unambiguously be detected. Molecular analyses of primary tissues by PCR or RT-PCR in contrast are much more critical because 'contamination' of the samples even with small fractions of stromal cells would give rise to false positive results.
In MRI-H215 and HT-3, we have identified and characterized hybrid transcripts of Smad4 coding sequences fused to unrelated sequences derived from further downstream 18q21 regions. These are located at approximately 35 and 661 kb downstream of Smad4 exon 9 and presumably mark the furthest possible extent of the deletions in the two samples. To our knowledge, naturally occurring hybrid Smad4 transcripts have not The percentage of positive tumor cells was scored as follows: (0) o5%;
(1) >5-35%; (2) >35-65%; (3) 65%
Smad4 deficiency in cervical carcinoma cells SE Baldus et al been reported before. The hybrid transcripts would encode truncated Smad4 proteins of 454 (HT-3) and 489 (MRI-H215) amino-acid residues, respectively, in which the MH2 domain is affected. However, the predicted truncated Smad4 proteins could never be detected in sensitive Western blots with lysates of the two cell lines. A possible explanation for this absence is that the truncated proteins are unstable. It has been shown that missense mutations either in the MH1 domain or in the C-terminal part of MH2 or C-terminal truncations result in loss of Smad4 protein expression due to strongly reduced protein stability (Wilentz et al., 2000a; Maurice et al., 2001) . As the Smad proteins mediate TGF-b responses and loss of the tumor suppressor Smad4 is believed to represent one of the molecular mechanisms resulting in TGF-b resistance, we have then measured responses of the cell lines to treatment with exogenous TGF-b. No clearcut correlation of Smad4 status with responsiveness to TGF-b-induced growth inhibition could be detected. There are Smad4-positive but TGF-b-resistant lines like HeLa, C33A and ME180, and also Smad4-negative lines like HT-3 retaining some degree of TGF-b responsiveness.
Accumulating evidence from our work and others suggests that loss of Smad4 and the acquisition of TGFb resistance are independent events in the carcinogenic process. We have shown previously that re-expression of Smad4 in cancer cells of the colon and pancreas was adequate to suppress tumor growth, while TGF-b resistance was retained (Schwarte-Waldhoff et al., 1999; Schwarte-Waldhoff et al., 2000) . Also, re-expression of Smad4 in C4-II cells was not adequate to restore TGF-b responsiveness even at high Smad4 expression levels (Klein-Scory et al., submitted).
Growth inhibitory responses are mediated through various mechanisms including repression of c-myc and induction of the CDK inhibitors p21 and p15 and are funneled through the retinoblastoma protein pRB and its relatives p107 and p130. The pRB pathway in cervical cancers, however, is generally disrupted by the HPV E7 oncoprotein (Helt and Galloway, 2003) . It has recently been reported that the E7 protein physically interacts with Smad2, Smad3 and Smad4 (Lee et al., 2002) . So, in addition to its well-known effects on pRB, E7 directly targets the Smad proteins that mediate TGF-b signalling. In conclusion, TGF-b resistance of cervical carcinoma cells may be acquired through mechanisms unrelated to loss of Smad4.
Ultimately, Smad4 expression analysis in tissue samples of the uterine cervix showed that functional inactivation of Smad4 is confined to malignant stages of the carcinogenic process: 10 out of 41 cases with squamous cell carcinoma were Smad4 negative and another 15 cases demonstrated strong reductions in the percentage of Smad4-positive cells. In contrast, Smad4 staining in cervical intraepithelial neoplasia with mild or moderate dysplasia was unaltered as compared to the normal squamous epithelium and was only slightly reduced in four out of 20 cases with severe dysplasia. These results are in good agreement with data recently published by others who examined Smad4 expression in small numbers of preneoplastic and malignant cervical tissue samples by semiquantitative RT-PCR (Maliekal et al., 2003) . They are also somewhat reminiscent to the situation in pancreatic carcinogenesis, where loss of Smad4 occurs concurrent with the acquisition of invasiveness (Wilentz et al., 2000b; Luettges et al., 2001) .
Notably, loss of chromosome 18q in cervical squamous carcinomas has previously been correlated with poor prognosis (Kersemaekers et al., 1998b; Dellas et al., 1999; Harima et al., 2001) . Moreover, 18q-deficient cervical cancers displayed a significantly worse response to radiotherapy, the most important nonsurgical treatment of cervical cancer (Harima et al., 2001) . Here, we report Smad4 deficiency in every fourth case of cervical cancers under study. It will be of interest to analyse in larger follow-up studies whether Smad4 inactivation in cervical cancers is associated with clinical prognosis.
Materials and methods
Cervical carcinoma cell lines
Cells of lines C4-I, C4-II, SiHa, CaSki, ME180, HT-3, C33A and MS751 were obtained from the American Type Culture Collection (Rockville, MD, USA), cell lines HeLa, MRI-H186, MRI-H196 and MRI-H215 from the Tumor bank of the German Cancer Research Center and 444 cells (HeLa Â normal fibroblast hybrid cell line) from Dr Eric Stanbridge (University of California, Irvine, CA, USA). HeLa cells were also obtained from additional sources. The identity of all HPV-positive cell lines was verified by Southern blot analysis using HPV type-specific DNA fragments as radiolabelled probes. In addition, PCR reactions specifically amplifying the integrated HPV18 DNA together with the flanking cellular sequences were performed for C4-I/C4-II and HeLa. All cells were maintained in DMEM (pH 7.2) supplemented with 10% FCS, 2 mM glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin.
Protein preparation and Western blot analysis
Cells were lysed in NP-40 lysis buffer (25 mM Tris HCl, pH 7.4, 0.5% NP-40, 100 mM NaCl, 1 mM EDTA) containing a protease inhibitor cocktail (Roche, Mannheim, Germany) and 1 mM PMSF. Proteins were subjected to standard SDS-PAGE and immunoblot analysis was performed as described (Schwarte-Waldhoff et al., 1999) . The blots were incubated with monoclonal antibodies against Smad4 (anti-Smad4 clone B8; dilution 1 : 500, Santa Cruz Biotechnology, Santa Cruz, CA, USA), followed by exposure to peroxidase-conjugated secondary antibody and developed using the enhanced chemoluminescent detection system (ECL, Amersham Buchler, Ismaning, Germany).
Northern and Southern blots
RNA was isolated by using a commercial kit (RNeasy, Qiagen, Hilden, Germany). Poly(A) þ -RNA was selected using dynabeads oligo(dT) 25 (Dynal Hamburg, Germany) . Northern blots and hybridization were performed as described (Schwarte-Waldhoff et al., 1999) . High-molecular-weight genomic DNA was isolated by standard procedures. For Southern blot analysis, 10 mg of genomic DNA were completely digested with HindIII or double-digested with HindIII Smad4 deficiency in cervical carcinoma cells SE Baldus et al and EcoRI, subjected to standard agarose gel electrophoresis and blotted. Hybridizations were performed according to standard procedures using exon-specific probes or the complete Smad4 coding sequence, as indicated in the figures.
PCR and RT-PCR amplification
RT was performed using SuperScript II (Invitrogen, Karlsruhe, Germany). For PCR, either Taq DNA polymerase (Invitrogen) or Titanium Taq DNA polymerase (BD Biosciences, Heidelberg, Germany) was used. Primer pairs for amplification of Smad4 genomic or cDNA sequences were selected by computer programs on the basis of the reference sequences NT_010966 (genomic sequence) and BC002379 (cDNA). For amplification of the 3 0 -ends of truncated Smad4 mRNAs in HT-3 and MRI-H215, a modified version of the RT-PCR method described by Klaes et al. (1999) was used. In brief, RT was primed with the oligonucleotide (dT) 17 -p3 (5 0 -GACTCGAGTCGACATCGA-(T) 17 ). Nested PCR was then performed in the first round with the Smad4-specific primer 5 0 -TAGCATCAGGGCCTCAGC (located in exon 5) and reverse primer p3, and in the second round with the Smad4-specific primer 5 0 -TCACAATGAGCTTGCATTCC (located in exon 7) and (dT) 17 -p3. PCR products were cloned into the vector pCR4Blunt-TOPO (Invitrogen, Karlsruhe, Germany). Smad4-positive clones were identified by hybridization with a labelled Smad4 cDNA probe, and the inserts of positive clones were sequenced.
Analysis of TGF-b response
For the analysis of growth responses to TGF-b, cells were plated on 60 mm dishes in standard medium. Medium was replaced with serum-reduced medium (0.5% fetal calf serum) when cells reached a confluency of approximately 30%, and recombinant transforming growth factor b1 (R&D systems) was added at a concentration of 5 ng/ml 24 h later. After 24 h, cells were fixed in 100% methanol for 30 min at À201C, centrifuged and resuspended in 0.1% Triton -X-100 in PBS containing propidium iodide (40 mg/ml; Sigma chemicals, Deisenhofen, Germany) and RNase (60 mg/ml; Sigma Chemicals) and incubated at 41C for 1 h. DNA content was measured using a flow cytometer (Beckman Coulter, Krefeld, Germany) and the cell-cycle distribution was calculated using the Phoenix Multicycle for Windows cell-cycle analysis software. A minimum of 10 000 events were measured for each sample. Each analysis was performed in triplicate for TGF-b-treated and untreated control cells.
Specimen selection
Tissue specimens containing invasive cervical squamous cell carcinomas from 41 patients were derived from the files of the Institute of Pathology, Mannheim, Germany, and 40 specimens of cervical biopsies exhibiting CIN were retrieved from the archives of the Institute of Pathology of the University of Cologne, Germany. All samples were fixed in 5% formaldehyde and embedded in paraffin. The hematoxylin and eosinstained slides from each case were screened for selection of adequate tissue blocks. The grade of dysplasia of CIN lesions was defined according to current WHO criteria.
Immunohistochemistry
The tissue specimens containing carcinoma or intraepithelial neoplasia, respectively, were cut (5-mm thick sections) and deparaffinized by routine histological techniques. After dewaxing, the slides were pretreated in a microwave (6 Â 5 min) at 600 W in citrate buffer, pH 6.0. Endogenous peroxidase was blocked by 1% H 2 O 2 in methanol for 30 min at room temperature (RT) and unspecific protein binding was reduced by addition of normal swine serum (1 : 20, DAKO, Hamburg, Germany) for 30 min at RT. Primary Smad4-specific monoclonal antibody (clone B8; dilution 1 : 50, Santa Cruz Biotechnology, Santa Cruz, CA, USA) was incubated overnight at 41C. Normal mouse serum was applied as negative control. A labelled streptavidin-biotin immunostaining procedure was performed as described previously (Baldus et al., 1998) . In brief, biotinylated rabbit-anti-mouse-immunoglobulins E413 (DAKO) and streptavidin-peroxidase-conjugate P397 (DAKO) were added for 30 min at RT, respectively. The reaction was visualized by 200 mg/ml 3-amino-9-ethylcarbazol in 50 mM sodium acetate buffer containing 5% dimethylformamide and 0.01% H 2 O 2 . Counterstaining with hematoxylin and embedding in glycerol jelly followed.
Evaluation of Smad4 expression
Smad4 protein expression in tissues was evaluated independently by two pathologists (SEB, DS). A deviation was observed in less than 5% of the specimens. In these cases, a consensus could be achieved. Non-neoplastic epithelium, stromal fibroblasts and lymphoid cells served as internal Smad4-positive controls. The percentage of positive tumor cells was evaluated and scored as follows: specimens containing 0-5% reactive carcinoma cells were regarded as negative (Maitra et al., 2000; Salovaara et al., 2002 ) (Score 0); >5-35%: (1); >35-65%: (2); >65%: (3).
